BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38886004)

  • 21. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.
    Miloslavsky EM; Lu N; Unizony S; Choi HK; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Fervenza F; Monach PA; Specks U; Stone JH
    Arthritis Rheumatol; 2016 Dec; 68(12):2945-2952. PubMed ID: 27428559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.
    Sandin C; Eriksson P; Segelmark M; Skogh T; Kastbom A
    Clin Exp Immunol; 2016 May; 184(2):208-15. PubMed ID: 26762653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An unusual presentation of propylthiouracil-induced anti-MPO and PR3 positive ANCA vasculitis with associated anti-GBM antibodies, IgA nephropathy and an IgG4 interstitial infiltrate: a case report.
    Galante JR; Daruwalla CP; Roberts ISD; Haynes R; Storey BC; Bottomley MJ
    BMC Nephrol; 2020 Jul; 21(1):295. PubMed ID: 32703233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays.
    Damoiseaux J; Csernok E; Rasmussen N; Moosig F; van Paassen P; Baslund B; Vermeersch P; Blockmans D; Cohen Tervaert JW; Bossuyt X
    Ann Rheum Dis; 2017 Apr; 76(4):647-653. PubMed ID: 27481830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.
    Rao DA; Wei K; Merola JF; O'Brien WR; Takvorian SU; Dellaripa PF; Schur PH
    J Rheumatol; 2015 May; 42(5):847-52. PubMed ID: 25834211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ANCA-positive vasculitis: Clinical implications of ANCA types and titers.
    Domingues VM; Machado B; Santos J
    Rev Assoc Med Bras (1992); 2016; 62(5):434-40. PubMed ID: 27656853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
    Weiner M; Bjørneklett R; Hrušková Z; Mackinnon B; Poulton CJ; Sindelar L; Mohammad AJ; Eriksson P; Gesualdo L; Geetha D; Crnogorac M; Jayne D; Hogan SL; Geddes C; Tesar V; Aasarød K; Segelmark M
    Nephrol Dial Transplant; 2019 Feb; 34(2):301-308. PubMed ID: 29718465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ANCA-associated vasculitis: report from Korea.
    Kim HW; Song YW
    Clin Exp Nephrol; 2013 Oct; 17(5):708-711. PubMed ID: 23292177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical features and treatment outcomes of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV): A retrospective analysis of 235 patients from a nationwide survey in Japan.
    Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Kunimoto Y; Matsui T; Sakaguchi H; Okada M; Watanabe T; Inagaki A; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T
    Mod Rheumatol; 2017 Jan; 27(1):87-94. PubMed ID: 27166750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides.
    Holle JU; Herrmann K; Gross WL; Csernok E
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S66-9. PubMed ID: 22512915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
    Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
    Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.
    Moxey J; Huq M; Proudman S; Sahhar J; Ngian GS; Walker J; Strickland G; Wilson M; Ross L; Major G; Roddy J; Stevens W; Nikpour M
    Arthritis Res Ther; 2019 Feb; 21(1):57. PubMed ID: 30764870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis.
    Hakroush S; Tampe D; Ströbel P; Korsten P; Tampe B
    Front Immunol; 2021; 12():737708. PubMed ID: 34759920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission.
    Ohlsson S; Wieslander J; Segelmark M
    Clin Exp Immunol; 2003 Mar; 131(3):528-35. PubMed ID: 12605707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-LAMP-2 Antibody Seropositivity in Children with Primary Systemic Vasculitis Affecting Medium- and Large-Sized Vessels.
    Akbaba TH; Toor KK; Mann SK; Gibson KM; Alfaro GA; Balci-Peynircioglu B; Cabral DA; Morishita KA; Brown KL;
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ANCA testing: the current stage and perspectives.
    Csernok E
    Clin Exp Nephrol; 2013 Oct; 17(5):615-618. PubMed ID: 23180043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type.
    Wallace ZS; Fu X; Harkness T; Stone JH; Zhang Y; Choi H
    Rheumatology (Oxford); 2020 Sep; 59(9):2308-2315. PubMed ID: 31846030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis.
    Holding S; Fisher VJ; Abuzakouk M
    Ann Clin Biochem; 2015 Mar; 52(Pt 2):297-301. PubMed ID: 24723621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization.
    Hagen EC; Daha MR; Hermans J; Andrassy K; Csernok E; Gaskin G; Lesavre P; Lüdemann J; Rasmussen N; Sinico RA; Wiik A; van der Woude FJ
    Kidney Int; 1998 Mar; 53(3):743-53. PubMed ID: 9507222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.